Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

GHK-Cu and AHK-Cu peptides show limited success for hair loss, with skepticism about their effectiveness and concerns about misleading claims. Users report better results when combined with treatments like finasteride, dutasteride, minoxidil, and other methods.

A 26-year-old male is still experiencing hair loss after a year of using Dutasteride and is considering using CB0301 (Breezula) to block all androgens on his follicles. He is looking for a reliable source to purchase CB0301 and inquires about the availability of a premade solution.

The conversation discusses the tension theory of baldness, suggesting that over-developed masseter muscles may harm hair follicles. Botox injections to relax these muscles reportedly led to an 18% increase in hair count in men with AGA.

The user is concerned about whether previous use of anti-androgens like fluridil, which caused side effects, will affect future use of finasteride. They have used finasteride briefly in the past and are considering using it again.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.

The conversation discusses experiences with hair loss treatments containing RootBioTec and Anagain. Users share their results and compare these treatments to Minoxidil, finasteride, and RU58841.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

Dutasteride may cause retrograde alopecia, with users experiencing hair loss on the neck and sides. Some users report slight improvement in hair thickness on top but no overall regrowth.

The conversation discusses potential future hair loss treatments, including SCUBE3, hair follicle cloning, and GT20029, with mentions of past disappointments like CosmeRNA and hopes for treatments like Verteporfin for infinite donor hair.

A 23-year-old with hair loss uses finasteride, minoxidil, and other treatments, considering adding dutasteride due to hairline recession. They seek advice on dutasteride's effectiveness and sourcing.

Breezula's development has stalled, leaving users disappointed. The conversation includes skepticism about its approval and effectiveness.

A 21-year-old male has been experiencing persistent hair loss despite using treatments like dutasteride, finasteride, RU58841, minoxidil, and ketoconazole. Suggestions include checking for hormonal issues, nutritional deficiencies, or allergies, and consulting a doctor for professional advice.

An 18-year-old male stopped using finasteride due to side effects and plans to start topical dutasteride, considering it a potential solution with fewer side effects. He continues using minoxidil despite no noticeable results and is exploring other treatments like RU58841.

A person with alopecia universalis is considering using Xeljanz but is advised that Olumiant is more effective for their condition. They are under a dermatologist's care and should expect gradual progress, as follicles dormant for 20 years are challenging to reactivate.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

Hair loss may be influenced by mechanical tension and inflammation, with the hi-c5 protein amplifying androgen effects, leading to follicle miniaturization. Treatments like finasteride, minoxidil, and scalp massages are suggested to manage hair loss.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

A 35-year-old had a hair transplant with 3,153 grafts at HLC Ankara, experiencing some pain and numbness but pleased with the density and results. The procedure cost $10,000, and the user has been using finasteride for over 13 years.

The conversation discusses concerns about a new rule affecting orders of hair loss treatments like Minoxidil, finasteride, and RU58841. Users are worried about the impact on their ability to obtain these products.

The conversation is about a user ordering Dutas (dutasteride) from a website called emedicalwala, facing issues with the order and refund, and eventually receiving the product. The user advises against ordering from emedicalwala again despite finally receiving the softgels.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

Avoid burning or scarring the scalp for hair growth; instead, use treatments like finasteride, minoxidil, or consider a hair transplant. Microneedling should be done carefully, and extreme methods can cause harm.

The user experienced increased shedding and an itchy scalp after switching from Ascend to Aurobindo finasteride. They are considering switching to dutasteride and are concerned about elevated estrogen levels and the effectiveness of adding minoxidil later.

A person is experimenting with microneedling on one temple while using Minoxidil to address hair loss. They plan to needle weekly and apply Minoxidil twice daily, avoiding application around needling sessions.

Quitting RU58841 after over two years reduced scalp itching and inflammation, despite concerns about losing hair gains. The user continues using finasteride and oral minoxidil.

The conversation discusses hair loss treatments, including dutasteride, oral minoxidil, finasteride, and potential additions like topical finasteride, minoxidil, micro-needling, and topical anti-androgens such as RU58841. The effectiveness and worth of these treatments, including localized dutasteride mesotherapy, are considered.

Triple Hair Inc. developed a new topical treatment, TH07, combining Finasteride, Latanoprost, and Minoxidil for androgenic alopecia. Users discussed its effectiveness compared to other treatments and shared their own product combinations.

The conversation critiques the influence of "Clavicular" on young men regarding hair loss treatments, highlighting the dangers of following unscientific advice and the rise of body dysmorphia. It emphasizes the importance of safe, medically advised treatments like minoxidil, finasteride, and dutasteride, while warning against reckless experimentation and early surgeries.

A 21-year-old male has been using finasteride, dutasteride, and oral minoxidil for hair loss without success and is considering trying RU58841, pyrilutamide, or clascoterone. Another user suggests checking vitamin levels, health conditions, and protein intake.